Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal–Bolus): Exploratory Randomized Trial in Type 2 Diabetes
详细信息 查看全文
- 作者：Wan Mohamaed Wan Bebakar ; Louis Chaykin ; Malene Lundgren Hersløv…
- 关键词：Glycemic control ; Insulin degludec/insulin aspart ; Insulin intensification
- 刊名：Diabetes Therapy
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：8
- 期：1
- 页码：197-205
- 全文大小：646KB
- 刊物主题：Internal Medicine; Diabetes; Cardiology; Endocrinology;
- 出版者：Springer Healthcare
- ISSN：1869-6961
- 卷排序：8
文摘
IntroductionIn a preceding trial comparing two different titration schemes, insulin degludec/insulin aspart (IDegAsp) showed good efficacy for achieving HbA1c <7% when administered twice daily (BID) in patients with uncontrolled type 2 diabetes (T2D). However, poor glycemic control persisted in a minority of patients. The current exploratory trial investigated the efficacy and safety of intensifying IDegAsp BID treatment in these patients by either adding a once-daily (OD) bolus injection of insulin aspart (IAsp) or by switching to a basal–bolus regimen of insulin degludec (IDeg) plus IAsp taken three times a day (TID).